- This event has passed.
BioBreakfast: The Victorian Heart Hospital – Driving innovation in cardiovascular care
June 11, 2019 @ 7:30 am - 9:00 am AEST
Event Navigation
BioMelbourne Network are hosting a series of quarterly events in 2019, sponsored by the Victorian State Government (DJPR), with the theme ‘shaping the future of health’ with a view to align industry and economic development in Victoria with future healthcare needs.
For the second event in the series we will be hearing from Professor Stephen Nicholls, Director of MonashHeart, who will be giving a presentation on an exciting new initiative, the Victorian Heart Hospital. He will cover the journey and progress to date and the opportunities for the future – focusing on strengthening links with science researchers based at Monash University, catalysing translational and clinical research, and fostering industry engagement for innovation in cardiovascular care.
The keynote presentation will be followed by a panel discussion on Victoria’s current cardiovascular capabilities where Sabeen Shaikh, COO, the Medtech Actuator will facilitate Q&A with our expert panel drawing on their differing experiences across medical technology/devices, regenerative medicine, clinical trials, and industry collaborations.
Event details
Date: Tuesday 11th June 2019
Time: 7.20 am – Registration; 7.30 am – Networking Breakfast; 8.00 am to 9.00 am – Presentation and Panel Discussion
Venue: Swanston Hall, Melbourne Town Hall, 90-130 Swanston Street, Melbourne VIC 3000
Cost: BioMelbourne Network Members – $65, Non Members – $130 (Prices include GST)
Speaker: Professor Stephen Nicholls, Director, MonashHeart
Joining Professor Nicholls on the Panel:
Dr Deama Amr, Clinical Research Manager, Cardio Vascular Group, Coronary & Structural Heart, Medtronic
A/Professor Enzo Porrello, Group Leader, Heart Regeneration, Murdoch Children’s Research Institute
A/Prof Leeanne Grigg, Divisional Director – Cardiovascular, Renal & Endocrine Services, Director of Cardiology, Royal Melbourne Hospital
Prof. Robert Whitbourn, Director of Cardiology, St Vincent’s Private Hospital Melbourne, Director, Cardiac Catheterisation Lab & Coronary Intervention, St. Vincent’s Hospital Melbourne
Panel moderated by: Sabeen Shaikh, COO, The Medtech Actuator
Check if your organisation is a member
This event is sponsored by
About the speakers
Professor Stephen Nicholls, Director, MonashHeart
Professor Stephen Nicholls was appointed to the position of Director of MonashHeart, Monash Health and Professor of Cardiology, Monash University in October 2018.
Prior to this, he was the Deputy Director and Heart Health Theme Leader at the South Australian Health and Medical Research Institute, Professor of Cardiology at the University of Adelaide and a cardiologist at the Central Adelaide Local Health Network.
He is a Principal Research Fellow of the National Health and Medical Research Council, an inaugural Fellow of the Australian Academy of Health and Medical Sciences and is Honorary Secretary of the Cardiac Society of Australia and New Zealand.
His work spans the translational spectrum from the lab bench to the bedside, with a focus on understanding the factors that promote plaque formation, novel vascular imaging and leadership of large scale clinical trials of new therapies designed to reduce the risk of heart disease.
He has extensive academic and industry collaborations, having raised more than $100 million in research funding and has written more than 770 manuscripts, book chapters and conference proceedings.
Dr Deama Amr, Clinical Research Manager, Cardio Vascular Group, Coronary & Structural Heart, Medtronic
Dr Deama Amr is a Clinical Research Manager for Medtronic Australasia’s Cardiac and Vascular Group, successfully supporting the business in establishing a clinical trial presence in Australia and New Zealand. Over the past five years, Dr Amr has identified barriers to the implementation of global clinical trials in the region, expanding the footprint of the clinical trial portfolio from two, to more than 12, during this timeframe. Her work has been rewarded through multiple company awards related to streamlining and expanding clinical trials in ANZ; and she has also been recognised for her fierce leadership of the ANZ Chapter of the Medtronic Women’s Network from 2016-2018. Before the move to the medical device industry, Dr Amr, completed a PhD in Pharmacology from the University of Sydney, and joined industry based clinical trials through the National Centre for HIV, Epidemiological & Clinical Research (NCHECR). From there she worked with Abbott Australasia on project management and clinical trial execution on a number of their therapeutic areas, including HIV, Rheumatoid Arthritis and Psoriasis, before moving to the George Institute to lead the APAC clinical operations of a number of Cardiovascular trials.
A/Professor Enzo Porrello, Group Leader, Heart Regeneration, Murdoch Children’s Research Institute
A/Prof Enzo Porrello is a National Health and Medical Research Council Career Development Fellow and Heart Foundation Future Leader Fellow who heads the Cardiac Regeneration Group at the Murdoch Children’s Research Institute and The University of Melbourne. A/Prof Porrello’s research group are working towards the development of novel regenerative therapies for children and adults with heart failure.His research achievements have been recognised by a number of prestigious awards including the Metcalf Prize for Stem Cell Research, Heart Foundation Paul Korner Innovation Award, Heart Foundation Queensland Researcher of the Year, A.K. McIntyre Prize (Australian Physiological Society) and the UT Southwestern Postdoctoral Achievement Award.
A/Prof Leeanne Grigg, Divisional Director – Cardiovascular, Renal & Endocrine Services, Director of Cardiology, Royal Melbourne Hospital
A/Prof Leeanne Grigg is the Divisional Director of Cardiovascular, Renal & Endocrine Services, Head of Cardiology, as well as Director of the Adult Congenital Cardiac Service, at the Royal Melbourne Hospital, Parkville, Victoria and on the Steering Committee of the Congenital Heart Alliance Australia and New Zealand. She is also Head of the Combined Congenital Cardiac Pregnancy service run conjointly with the Royal Women’s Hospital. After initial training at the Royal Melbourne Hospital, and further training at Toronto Hospital in Ontario Canada, A/Prof Grigg has been involved in the development and expansion of the congenital cardiac service in collaboration with the Cardiology Department at the Royal Children’s Hospital. In addition to providing clinical care to the congenital heart patients, she is involved in teaching and research in this area and in training other cardiologists in the growing subspeciality of Adult Congenital Cardiac Disease.
Prof. Robert Whitbourn, Interventional Cardiologist & the Director of Cardiac Catheterization Laboratories at St Vincent’s Hospital and Director of Cardiology at St Vincent’s Private Hospital Melbourne
Professor Rob Whitbourn is an Interventional Cardiologist and the Director of Cardiac Catheterization Laboratories at St Vincent’s Hospital and Director of Cardiology at St Vincent’s Private Hospital Melbourne
He is a Fellow of the Cardiac Society of Australia and New Zealand and an internationally recognised leader in Interventional Cardiology and novel devices. His research career spans over 20 years, including 2 years as Interventional Cardiology and Research Fellow at Stanford University Medical Centre in the USA.
He has been principal investigator on multiple research projects and numerous first-in-man cardiovascular technologies ranging from novel coronary drug eluting and bioabsorbable stents, TAVI ( percutaneous Aortic valve implants) and pioneered renal sympathetic denervation (RDN), as Principal Investigator for the Symplicity HTN1 study and performed the first cases of renal sympathetic denervation in the world.
He has a substantial publication track record, is an author of more than 150 scientific papers, has given numerous invited lectures at national or international scientific meetings and has been successful with research funding to the value of over $12 million to date.
Professionally, Prof. Whitbourn is extremely active. He is on the Executive of ANZET (Australia & New Zealand Endovascular Therapies) Group as a founding member and is Chair of the Live Case Program for the annual ANZET meeting. He has also been on Faculty at the major European and American Interventional Cardiology meetings, EuroPCR & TCT, over the last 15 years.
He is a Fellow of the Cardiac Society of Australia and New Zealand and an internationally recognised leader in Interventional Cardiology and novel devices. His research career spans over 20 years, including 2 years as Interventional Cardiology and Research Fellow at Stanford University Medical Centre in the USA.
He has been principal investigator on multiple research projects and numerous first-in-man cardiovascular technologies ranging from novel coronary drug eluting and bioabsorbable stents, TAVI ( percutaneous Aortic valve implants) and pioneered renal sympathetic denervation (RDN), as Principal Investigator for the Symplicity HTN1 study and performed the first cases of renal sympathetic denervation in the world.
He has a substantial publication track record, is an author of more than 150 scientific papers, has given numerous invited lectures at national or international scientific meetings and has been successful with research funding to the value of over $12 million to date.
Professionally, Prof. Whitbourn is extremely active. He is on the Executive of ANZET (Australia & New Zealand Endovascular Therapies) Group as a founding member and is Chair of the Live Case Program for the annual ANZET meeting. He has also been on Faculty at the major European and American Interventional Cardiology meetings, EuroPCR & TCT, over the last 15 years.
Sabeen Shaikh, COO, The Medtech Actuator
Sabeen Shaikh is a visionary and strategic commercial business leader, who is well-known on the global industry platform. Originally from the US, she is now the Chief Operating Officer of The Actuator bringing her 15 years of corporate experience to the startup world. Sabeen has been involved in creating sustainable and scalable business portfolios for large multi-national corporates, redefining clinical guidelines at the national and global level for surgical procedures and leading commercial teams to hyper accelerated revenue growth.
Sabeen is passionate about disruptive technologies, innovations for unmet medical needs and healthcare access to underserved populations.
Sabeen is passionate about disruptive technologies, innovations for unmet medical needs and healthcare access to underserved populations.
